Revvity

Revvity

Yahoo Finance • 2 days ago

Cell-Based Assay & High Content Screening Market Report Reveals Why Technology Is Outpacing the Market, Profiling Thermo Fisher, Roche, Sartorius, Revvity & 50 Other Key Players

Company Logo 281-Page Report Tracks Post-Pandemic Research Growth Across Pharma, Research and Industry/Cosmetic Users as 3D Assays, Automation and Immuno-oncology Reshape Drug Discovery Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Cell-Bas... Full story

Yahoo Finance • 6 days ago

Moderna, Illumina lead healthcare gains in September as medtech drags

[Close-Up Shot of Scientists Hands typing Data in Laptop in Laboratory] Tom Werner Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund (XLV [https://seekingalpha.com/symbol/XLV])... Full story

Yahoo Finance • 15 days ago

Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test

All three major US stock indexes fell in late-morning trading Thursday amid uncertainty in the Middl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 17 days ago

Capitalize on the Label-Free Detection Market Shift: Track How Danaher, Sartorius, Agilent, Bruker and Revvity Are Disrupting R&D ROI and Reshaping Global Revenue Through 2030

Company Logo AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows. Dublin, Sept. 22, 2026 (GLOBE... Full story

Yahoo Finance • 17 days ago

Capitalize on High Content Screening Disruption: Decode How Thermo Fisher Scientific, Danaher, Revvity, and Yokogawa Are Reshaping Global R&D ROI and Revenue

Company Logo High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids. Dublin, Sept. 22, 2026 (GLOBE... Full story

Yahoo Finance • 19 days ago

Notable healthcare headlines for the week: Novo Nordisk, GE HealthCare, and Eli Lilly in focus

Wall Street's major market averages finished mixed as Treasury yields rebounded, rekindling concerns about a deteriorating macroeconomic backdrop. The S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500#source=url_first_level%3Amarket-n... Full story

Yahoo Finance • 21 days ago

Revvity slips as CFRA downgrades on limited near-term upside

[Wall Street sign in Lower Manhattan, NYC] georgeclerk Revvity (RVTY [https://seekingalpha.com/symbol/RVTY]) shares fell on Friday following a five-day winning streak as CFRA downgraded the life sciences company to Hold from Buy, citing a... Full story

Yahoo Finance • 23 days ago

Stock futures rise as Fed rate decision takes center stage

[Wall Street street sign in Manhattan financial district] Alexey_Fedoren Stock index futures were higher on Wednesday as investors focused on the Federal Reserve's interest rate decision. Dow futures (INDU [https://seekingalpha.com/symbo... Full story

Yahoo Finance • 24 days ago

Stocks making the biggest moves midday: Skyworks Solutions, Axon, Dave & Buster's, Revvity & more

Check out the companies making the biggest moves midday: Skyworks Solutions , Qorvo — The chipmakers popped, recovering from a sell-off in the previous session driven by safety concerns around artificial trade. Skyworks traded 10% higher,... Full story

Yahoo Finance • last month

Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others

Company Logo 500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein MarketResearch Use Recombinant Protein Market Dub... Full story

Yahoo Finance • last month

Healthcare August recap: Moderna jumps 156% as biotech shines; DaVita sinks

[Health Care Medical Concept] ogichobanov/iStock via Getty Images The healthcare sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 4.91% in August, outperforming the broader S&P 500 (SPY [https://seekingalpha.com/symbol/SPY]), whi... Full story

Yahoo Finance • last month

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity, Inc. RVTY is entering the second half of 2026 with stronger operating momentum. Raised guidance, double-digit Diagnostics growth and better cash generation have improved the earnings setup. The counterweight is valuation. RVTY al... Full story

Yahoo Finance • last month

Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings

Revvity has delivered a strong 57.5% return over the past year, while valuation checks send mixed signals. The Discounted Cash Flow (DCF) intrinsic value estimate suggests the stock is roughly in line with fair value, and market-based mult... Full story

Yahoo Finance • 2 months ago

Stock futures edge lower as traders focus on Strait of Hormuz reopening

[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov Stock index futures were lower on Tuesday as traders continued to focus on developments related to the reopening of the Strait of Hormuz. Dow futures (INDU [https://... Full story

Yahoo Finance • 2 months ago

1 Profitable Stock on Our Buy List and 2 We Find Risky

1 Profitable Stock on Our Buy List and 2 We Find Risky While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, "... Full story

Yahoo Finance • 2 months ago

Revvity outlines 2026 organic growth of 4% to 5% and adjusted EPS of $5.30 to $5.40, driven by diagnostics momentum and AI-linked demand

Earnings Call Insights: Revvity (RVTY) Q2 2026 MANAGEMENT VIEW * "I'm pleased to report that Revvity delivered strong results in the second quarter with pro forma organic growth of 3%, resulting in total revenue being above the high en... Full story

Yahoo Finance • 3 months ago

Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure

WALTHAM, Mass., July 20, 2026--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Company's sustainability, social and governance strategy, initiatives and performance. The annual report sh... Full story

Yahoo Finance • 3 months ago

3 Healthcare Stocks We Think Twice About

3 Healthcare Stocks We Think Twice About Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 10% ove... Full story

Yahoo Finance • 3 months ago

Q1 Earnings Roundup: Mettler-Toledo (NYSE:MTD) And The Rest Of The Research Tools & Consumables Segment

Q1 Earnings Roundup: Mettler-Toledo (NYSE:MTD) And The Rest Of The Research Tools & Consumables Segment The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how... Full story

Yahoo Finance • 3 months ago

3 Reasons to Avoid RVTY and 1 Stock to Buy Instead

3 Reasons to Avoid RVTY and 1 Stock to Buy Instead Revvity's 14.9% return over the past six months has outpaced the S&P 500 by 5.6%, and its stock price has climbed to $112.79 per share. This performance may have investors wondering how t... Full story